REVELATION BIOSCIENCES, INC. (REVB) Form 8-K — Aug 6, 2026

$REVBForm 8-KItems 2.02, 9.01Filed Aug 6, 2026, 4:19 PM ET0001193125-26-338097Original filing

Revelation Biosciences (NASDAQ: REVB) reported results for the three and six months ended June 30, 2026, holding $11.5 million in cash at quarter end, up from $10.7 million at December 31, 2025, helped by net proceeds from a January 2026 warrant inducement. Management said current cash is sufficient to fund operations only through the first quarter of 2027. Net loss for the second quarter was $3.3 million, or $0.87 per share, versus $2.4 million, or $28.04 per share, a year earlier, as operating cash use rose to $2.6 million from $1.9 million and total operating expenses grew to $3.7 million from $2.5 million.

Key figures

Eps: -$0.87 (Q2 2026 basic and diluted); -$3.41 (six months 2026)
Net Income: -$3,323,384 (Q2 2026); -$6,332,435 (six months 2026)
Total Assets: 12497932
Cash Position: $11,482,792 (June 30, 2026) vs $10,700,331 (Dec 31, 2025)
Shares Outstanding: 3908420
Runway: Cash sufficient to fund operations through Q1 2027
Gemini tam: $94 billion potential total addressable market per independent assessment
Total liabilities: 2430946
Ga expense q2 2025: 1143249
Ga expense q2 2026: 1743817
Rd expense q2 2025: 1317980
Rd expense q2 2026: 1918424
Total opex q2 2025: 2461229
Total opex q2 2026: 3662241
Stockholders equity: 10066986
Operating cash use q2 2026: $2.6 million vs $1.9 million in Q2 2025
Weighted avg shares q2 2025: 200668
Weighted avg shares q2 2026: 3829363

Price after filing

1 day: +2.7%7 days: -0.9%30 days: -9.8%

Close on the filing date to close N calendar days later (from $1.12). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.